At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02142 HBM HOLDINGS-B
Closed 11-06 16:08:52
10.380
-0.330
-3.08%
High10.670Low10.200Vol7.60M
Open10.260D1 Closing10.710Amplitude4.39%
Mkt Cap9.02BTradable Cap9.02BTotal Shares869.00M
T/O79.24MT/O Rate0.87%Tradable Shares869.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Harbour Biomed Appoints MS. Vivian Feng as Head of External Collaboration
THOMSON REUTERS  ·  11-05 14:57
Harbour Biomed Appoints MS. Vivian Feng as Head of External Collaboration
Press Release: Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration
Dow Jones  ·  11-05 14:57
Press Release: Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration
Movement Alert｜HBM HOLDINGS-B Intraday Rise 5.03% in Regular Trading, Buybacks and Biotech Strength Support Shares
Market Focus  ·  11-05 10:41
Movement Alert｜HBM HOLDINGS-B Intraday Rise 5.03% in Regular Trading, Buybacks and Biotech Strength Support Shares
Movement Alert｜HBM HOLDINGS-B Intraday Rise 5.16% in Regular Trading, Buyback and Biotech Sector Strength Support Shares
Market Focus  ·  11-04 13:32
Movement Alert｜HBM HOLDINGS-B Intraday Rise 5.16% in Regular Trading, Buyback and Biotech Sector Strength Support Shares
HBM HOLDINGS-B (02142) Spends About HK$4.7175 Million to Repurchase 500,000 Shares on November 3
Stock News  ·  11-03 21:48
HBM HOLDINGS-B (02142) Spends About HK$4.7175 Million to Repurchase 500,000 Shares on November 3
HBM Holdings-B Repurchases 200,000 Shares for HK$1.9514 Million on November 2
Stock News  ·  11-02
HBM Holdings-B Repurchases 200,000 Shares for HK$1.9514 Million on November 2
HBM Holdings Executes HK$1.95 Million Share Buyback and Issues 21,000 Award Shares, Leaving 869.71 Million Shares Outstanding
Bulletin Express  ·  11-02
HBM Holdings Executes HK$1.95 Million Share Buyback and Issues 21,000 Award Shares, Leaving 869.71 Million Shares Outstanding
HBM Holdings Updates Share Capital Structure after 200,000-Share Buyback and 196,000 New Shares for Award Scheme
Bulletin Express  ·  10-30
HBM Holdings Updates Share Capital Structure after 200,000-Share Buyback and 196,000 New Shares for Award Scheme
HBM Holdings-B (02142) Spends Approximately HK$1.9524 Million to Repurchase 200,000 Shares on October 30
Stock News  ·  10-30
HBM Holdings-B (02142) Spends Approximately HK$1.9524 Million to Repurchase 200,000 Shares on October 30
Movement Alert｜HBM HOLDINGS-B Falls 5.11% in Regular Trading, Pulls Back Despite Recent Drug Approval
Market Focus  ·  10-27
Movement Alert｜HBM HOLDINGS-B Falls 5.11% in Regular Trading, Pulls Back Despite Recent Drug Approval
HBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus
Simply Wall St.  ·  10-25
HBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus
Did China Drug Approval Just Shift HBM Holdings' (SEHK:2142) Investment Narrative?
Simply Wall St.  ·  10-24
Did China Drug Approval Just Shift HBM Holdings' (SEHK:2142) Investment Narrative?
HBM Wins China Approval for Batoclimab Injection
MT Newswires Live  ·  10-23
HBM Wins China Approval for Batoclimab Injection
HBM Holdings-B (02142): Batoclimab Subcutaneous Injection Approved by NMPA for Marketing to Treat Generalized Myasthenia Gravis
Stock News  ·  10-23
HBM Holdings-B (02142): Batoclimab Subcutaneous Injection Approved by NMPA for Marketing to Treat Generalized Myasthenia Gravis
Hbm Holdings - Nmpa Approves Batoclimab Injection for Generalized Myasthenia Gravis
THOMSON REUTERS  ·  10-23
Hbm Holdings - Nmpa Approves Batoclimab Injection for Generalized Myasthenia Gravis
Movement Alert｜HBM HOLDINGS-B falls 5.23% in Regular Trading, recent buyback disclosures offer limited support
Market Focus  ·  10-22
Movement Alert｜HBM HOLDINGS-B falls 5.23% in Regular Trading, recent buyback disclosures offer limited support
HBM Holdings Slightly Narrows Share Base After HKD 3.14 Million Buyback; Issues New Shares for Awards
Bulletin Express  ·  10-20
HBM Holdings Slightly Narrows Share Base After HKD 3.14 Million Buyback; Issues New Shares for Awards
HBM Holdings-B (02142) Spends HK$3.1408 Million to Repurchase 300,000 Shares on October 20
Stock News  ·  10-20
HBM Holdings-B (02142) Spends HK$3.1408 Million to Repurchase 300,000 Shares on October 20
HBM Holdings-B Spends HK$3.1494 Million to Buy Back 300,000 Shares on October 16
Deep News  ·  10-18
HBM Holdings-B Spends HK$3.1494 Million to Buy Back 300,000 Shares on October 16
HBM Holdings Cuts Free-Float by 0.03% via HKD 3.15 Million Buyback, Issues Shares for Post-IPO Award Scheme
Bulletin Express  ·  10-16
HBM Holdings Cuts Free-Float by 0.03% via HKD 3.15 Million Buyback, Issues Shares for Post-IPO Award Scheme

Introduction

Company Name.
HBM HOLDINGS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
Issue price:
--